Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:XLRN

Acceleron Pharma (XLRN) Stock Price, News & Analysis

Acceleron Pharma logo

About Acceleron Pharma Stock (NASDAQ:XLRN)

Advanced Chart

Key Stats

Today's Range
$178.75
$178.75
50-Day Range
$172.08
$179.68
52-Week Range
$108.82
$189.99
Volume
N/A
Average Volume
572,759 shs
Market Capitalization
$10.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acceleron Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
14th Percentile Overall Score

XLRN MarketRank™: 

Acceleron Pharma scored higher than 14% of companies evaluated by MarketBeat, and ranked 889th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Acceleron Pharma.

  • Earnings Growth

    Earnings for Acceleron Pharma are expected to grow in the coming year, from ($3.95) to ($3.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Acceleron Pharma is -42.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Acceleron Pharma is -42.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Acceleron Pharma has a P/B Ratio of 15.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for XLRN.
  • Dividend Yield

    Acceleron Pharma does not currently pay a dividend.

  • Dividend Growth

    Acceleron Pharma does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for XLRN.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Acceleron Pharma this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Acceleron Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.70% of the stock of Acceleron Pharma is held by insiders.

  • Percentage Held by Institutions

    90.35% of the stock of Acceleron Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Acceleron Pharma's insider trading history.
Receive XLRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acceleron Pharma and its competitors with MarketBeat's FREE daily newsletter.

XLRN Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Acceleron Banks on Muons for Colder Fusion
ORBIMED CAPITAL GP II LLC's Net Worth
XLRN Historical Data
See More Headlines

XLRN Stock Analysis - Frequently Asked Questions

Acceleron Pharma Inc. (NASDAQ:XLRN) released its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($0.98) by $0.18. The firm's quarterly revenue was up 51.6% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acceleron Pharma investors own include Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA) and Vertex Pharmaceuticals (VRTX).

Company Calendar

Last Earnings
11/04/2021
Today
7/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:XLRN
Employees
312
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$166.03 million
Net Margins
-226.01%
Pretax Margin
-225.99%

Debt

Sales & Book Value

Annual Sales
$92.52 million
Price / Cash Flow
N/A
Book Value
$11.74 per share
Price / Book
15.23

Miscellaneous

Free Float
60,116,000
Market Cap
$10.93 billion
Optionable
Optionable
Beta
0.13

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:XLRN) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners